Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Accumulated Expenses (2023 - 2025)

Historic Accumulated Expenses for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $20.4 million.

  • CG Oncology's Accumulated Expenses rose 8027.19% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 8027.19%. This contributed to the annual value of $14.7 million for FY2024, which is 4042.9% up from last year.
  • Per CG Oncology's latest filing, its Accumulated Expenses stood at $20.4 million for Q3 2025, which was up 8027.19% from $23.0 million recorded in Q2 2025.
  • CG Oncology's Accumulated Expenses' 5-year high stood at $23.0 million during Q2 2025, with a 5-year trough of $5.1 million in Q1 2024.
  • In the last 3 years, CG Oncology's Accumulated Expenses had a median value of $13.0 million in 2024 and averaged $13.5 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 4042.9% in 2024, then skyrocketed by 22235.79% in 2025.
  • CG Oncology's Accumulated Expenses (Quarter) stood at $10.4 million in 2023, then skyrocketed by 40.43% to $14.7 million in 2024, then soared by 39.26% to $20.4 million in 2025.
  • Its Accumulated Expenses was $20.4 million in Q3 2025, compared to $23.0 million in Q2 2025 and $15.7 million in Q1 2025.